Position in GUTS
as of Mar 31, 2026
· filed May 18, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Derivatives in GUTS
reported options exposure · as of Mar 31, 2026CallValue
$654,285
CallShares
1,428,571
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026ADAR1 Capital Management, LLC holds $1,760,528,411 across 192 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
1,804,703 | $240,494,721 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
|
960,863 | $117,782,586 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
3,157,008 | $111,726,513 | |
| 4 | IMVT |
Immunovant, Inc.
|
2,330,716 | $89,802,487 | |
| 5 | ZLAB |
Zai Lab Ltd
|
3,369,034 | $64,011,646 | |
| 6 | AGIO |
Agios Pharmaceuticals, Inc.
|
1,288,053 | $47,799,646 | |
| 7 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
1,222,080 | $45,730,233 | |
| 8 | CYTK |
Cytokinetics Inc
|
457,907 | $39,009,097 |
All Filings in GUTS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $654,285 | 1,428,571 | Call | Sole | 2026-05-18 | |
| 2025-12-31 | $3,142,856 | 1,428,571 | Call | Sole | 2026-02-18 | |
| 2025-09-30 | $20,824 | 13,097 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||